Also Known As
This article was last reviewed on
This article waslast modified on November 11, 2019.
What is multiple sclerosis?

Multiple sclerosis (MS) is a chronic disease that affects the central nervous system (CNS). It causes inflammation and the destruction of myelin. Myelin surrounds nerve fibers and acts like insulation on a wire, preventing "short-circuits" that divert a nerve signal from having its desired effects. The "demyelination" process interferes with nerve impulse transmission, affects muscular control, and causes a variety of sensory, motor, and psychological symptoms. Damage to the myelin usually resolves with time and symptoms subside, but repeated attacks can lead to a continual process of demyelination and remyelination, which produces nerve fiber scarring and progressive disability.

The cause of MS is unknown. It is thought to be an autoimmune process triggered by a virus, environmental factors, and/or a genetic predisposition. Typically, MS first appears and is diagnosed when individuals are between 20 and 50 years of age, although it can occur in young children. Two to three times more women are affected than men. It is more common in Northern European Caucasians than other ethnic groups and is seen in greater numbers in people who live in temperate climates than warm ones.

According to the National Multiple Sclerosis Society, MS affects about 2.3 million people worldwide. It is estimated that about 250,000 to 350,000 people in the U.S. have MS, according to the National Institute on Neurological Disorders and Stroke. The risk of developing this disease is estimated to be about 1 in 750 in the general population. In families with an affected member, the risk rises to 1 in 40, and it is about 1 in 4 for the identical twin of an affected person, strengthening the notion of a genetic component to the cause.

There is no single test that can conclusively diagnose MS. Instead, health practitioners look for a combination of factors to determine if a patient has MS. The factors are described in a document called the "McDonald Criteria," named for the doctor who chaired the 2001 panel of experts charged with establishing criteria for an accurate diagnosis. The document is updated regularly as new research improves our understanding of the disease. Physicians will consult a patient's medical history and a variety of clinical and laboratory tests to aid in their diagnosis. In applying the criteria for diagnosing MS, a healthcare practitioner must:

  • Determine that the CNS has been damaged in at least two places
  • Confirm that the damage occurred at separate times, more than one month apart
  • Rule out other conditions that cause a similar set of signs and symptoms

Once diagnosed, an individual may be classified as having one of several types of MS, based on signs and symptoms, frequency of relapses, rate of disease progression, and the number of areas that are damaged in the CNS:

  • Clinically Isolated Syndrome (CIS)
  • Relapsing-remitting (RRMS)
  • Secondary progressive (SPMS)
  • Primary progressive (PPMS)
Accordion Title
About Multiple Sclerosis
  • Signs and Symptoms

    Because MS can attack any area of the central nervous system, the signs and symptoms of MS are many and varied. They are associated with what the nerves in the affected area(s) are responsible for controlling. Symptoms of MS may come and go and their duration may last from days to months. Some of these include:

    • Sensory symptoms such as numbness, tingling, pain, burning, itching, facial pain, and visual disturbances
    • Motor symptoms such as speech impediments, weakness, tremor, difficulty walking, lack of coordination, constipation, and problems with the control of urination
    • Psychological symptoms such as mood swings, depression, and problems with thinking, learning, and memory
    • Fatigue occurs in up to 80% of those with MS.

    According to the National Multiple Sclerosis Society, about 85% of those with multiple sclerosis initially have relapsing-remitting MS. They experience periodic attacks or relapses followed by healing and symptom remission. Later in the course of the disease, about half develop secondary progressive MS. Their symptoms and disabilities worsen as they continue to have relapses but do not fully recover. About 15% of people with MS have a progressive form of the disease. They grow gradually worse without experiencing remissions.

  • Tests

    Although there is no single test or set of tests that can establish a diagnosis of multiple sclerosis (MS), there are three tests that are generally considered useful:

    Laboratory tests
    There are no laboratory tests that are completely specific for multiple sclerosis, but several laboratory tests are helpful in diagnosing or excluding this disease as the cause of a person's signs and symptoms. A few involve tests done on cerebrospinal fluid:

    • CSF Electrophoresis and Isoelectric Focusing—these are two methods for separating the proteins in a biological fluid. A patient's CSF and serum are evaluated side-by-side on a test surface using either of these two techniques. Following the separation step, a protein stain is applied to both specimens and the banding patterns that appear in the CSF and serum are compared to one another. The presence of two or more IgG bands in CSF that are not present in serum is a positive test for oligoclonal banding. About 90% of people with MS show oligoclonal banding in their CSF.
    • CSF Immunoglobulin G (IgG) Index—increased levels of CSF IgG can be due to excess production of IgG within the central nervous system, which is seen with MS and several other diseases. It can also be due to leakage of plasma proteins into the CSF, such as might occur with inflammation or trauma. To discriminate between these two possibilities, the IgG index is calculated from IgG and albumin measurements performed in CSF and serum:

      IgG index = [IgG (CSF) / IgG (serum)] / [Albumin (CSF) /Albumin (serum)]

      An elevated IgG index indicates increased production of IgG within the central nervous system. It is found in about 90% of MS cases.

    • Myelin basic protein—this is a major component of myelin. Increased concentrations of myelin basic protein in CSF indicate that demyelination is taking place. This process is not specific for MS, as other inflammatory diseases of the central nervous system can also elevate the amount of myelin basic protein in CSF. This test is not widely available; however, it may be used to assess disease activity in cases of established MS.

    Health practitioners may also test for diseases that can cause symptoms similar to MS to determine if they may be responsible for a patient's illness. Examples include:

    Non-laboratory tests

    • MRI (magnetic resonance imaging) scans allow healthcare practitioners to examine the brain. MRI can show both permanent scarring as well as new lesions. These scans are used to help diagnose MS and to track its progression over time. Improvements in MRI technology have significantly improved the ability to accurately diagnose MS at an early stage. Early diagnosis and treatment is key to minimizing the effects of the disease.

      In addition to the standard MRI, there are a variety of specialized techniques that may be performed, such as functional MRI, magnetic resonance spectroscopy, and diffusion-tensor MRI. The National Multiple Sclerosis Society (NMSS) web site has more information on the use of MRI in MS.

    • Visual evoked potentials (VEP) are electrical diagnostic studies that measure the speed of nerve transmissions (messages) in various parts of the brain. They are recordings of the nervous system's electrical response to visual stimuli. Damage to myelin can slow nervous system response time and VEP tests can reveal evidence of scarring along nerve pathways associated with vision. The NMSS web page has additional details about this test.

      Two other types of evoked potentials may be used, though less commonly. Brain stem auditory evoked potentials (BAEP) is a test that helps detect lesions in the brainstem causing delays in the transmission of sounds. Somatosensory evoked potentials (SSEP) is a test that applies a brief electrical stimulus to the wrist or ankle. It detects disruptions in the pathways from the arms and legs to the brain at very specific points of the central nervous system.

  • Treatment

    There is no cure for multiple sclerosis, but a variety of treatments are available that may be used to manage the condition. The goals of MS treatment are to slow the progression of the disease, relieve symptoms, and minimize the effects of acute attacks.

    • Several medications have been approved by the U.S. Food and Drug Administration (FDA) to help reduce the severity of the disease and slow progression. These are useful for many people with relapsing forms of MS.
    • Health practitioners may prescribe corticosteroids for short periods of time to help reduce inflammation and shorten the duration of relapses.
    • Other medications may be used to address specific symptoms, such as bladder and bowel problems, tremors, dizziness, pain, and problems walking, to name a few. Fatigue and depression sometimes associated with MS, for example, may be treated with appropriate antidepressants.

    For more on specific medications that may be prescribed, see the Treatments page on the National Multiple Sclerosis Society website.

    MS does not significantly decrease the lifespan of those who have it, but it can frequently and intermittently affect quality of life. People with MS usually work with a team of professionals who help support and monitor their condition and address their changing needs. Current MS research is directed toward understanding the cause of MS in hopes of developing better drugs to treat, if not cure or prevent the disease.

View Sources

Sources Used in Current Review

Aharoni, R. 2013. Autoimmunity Reviews. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Available online at Accessed April 9, 2016.

Browne, P., et al. 2014. American Academy of Neurology. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Available online at Accessed April 9, 2016.

National Multiple Sclerosis Society. 2016. What is MS? Available online at Accessed April 9, 2016.

National Multiple Sclerosis Society. CHANGES IN MULTIPLE SCLEROSIS DISEASE-COURSE (OR “TYPE”) DESCRIPTIONS. Available online at Accessed April 2016.

Multiple Sclerosis Association of America. 2016. Possible Causes of Multiple Sclerosis. Available online at Accessed April 9, 2016.

National Institute of Neurological Disorders and Stroke. 2015. Multiple Sclerosis: Hope Through Research. Available online at Accessed April 9, 2016.

Lublin et al. Defining the clinical course of multiple sclerosis; the 2013 revisions. Neurology 2014;83:278-286.

Sources Used in Previous Reviews

Thomas, Clayton L., Editor (1997). Taber's Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].

Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby's Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.

Espay, A. (2002 May 6, Updated). Multiple sclerosis [20 paragraphs]. MedlinePlus Medical Encyclopedia [On-line information]. Available online at

(2003 August 12). About MS What Is Multiple Sclerosis? National Multiple Sclerosis Society [On-line information]. Available online at

(2001 July 1, Reviewed). NINDS Multiple Sclerosis Information Page. NINDS [On-line information]. Available online at

Mayo Clinic Staff (2004 May 7). Multiple sclerosis. [On-line information]. Available online at

Kiriakopoulos, E. (2003 August 10, Updated). CSF oligoclonal banding. MedlinePlus Medical Encyclopedia [On-line information]. Available online at

(© 1995-2004). Multiple Sclerosis and Related Diseases, Introduction. The Merck Manual – Second Home Edition [On-line information]. Available online at

Holland, N. (2003 December). Overview of Multiple Sclerosis. MSNursing, NMSS [On-line information]. Available online at

(2002 Updated). Multiple Sclerosis: Hope Through Research. NINDS [On-line information]. Available online at

(© 2004). Immunoglobulin G, CSF Index and Immunoglobulin G/Albumin Ratio, CSF. ARUP’s Guide to Clinical Laboratory Testing [On-line information]. Available online at

(© 2004). Oligoclonal Banding and Multiple Sclerosis Panel. ARUP’s Guide to Clinical Laboratory Testing [On-line information]. Available online at

(© 2004). Myelin Basic Protein. ARUP’s Guide to Clinical Laboratory Testing [On-line information]. Available online at

(Updated 2008 December). Multiple Sclerosis: Hope Through Research. NINDS, National Institute of Health. Available online at Accessed March 2009.

Minden, S.and Frankel, D. (Updated May 2008). PLAINTALK: A Booklet about MS for Families. National Multiple Sclerosis Society. [On-line information]. Available online at Accessed March 2009.

Dangond, F. (Updated 2008 July 3). Multiple Sclerosis. [On-line information]. Available online at Accessed March 2009.

Brian R. Apatoff, B. (Revised August 2007). Multiple Sclerosis. Merck Manual for Healthcare Professionals. [On-line information]. Available online at Accessed March 2009.

(©2011) National Multiple Sclerosis Society. Treatments. Available online at Accessed April 2013.

(©2011) National Multiple Sclerosis Society. Diagnosing MS. Available online at Accessed April 2013.

(©2011) National Multiple Sclerosis Society. Diagnosis Criteria. PDF available for download at Accessed April 2013.

(August 14, 2012) National Institute on Neurologic Disorders and Stroke. Multiple Sclerosis. Available online at Accessed April 2013.

(Updated April 2013) Luzzio C. Multiple Sclerosis. Medscape Reference. Available online at Accessed April 2013.